Arrowhead Announces Push Into Obesity Space With Two Gene Therapies

Arrowhead Pharmaceuticals Advances Two New RNAi-Based Obesity Candidates

Preclinical Data and Development Plans Presented

Pasadena, California, May 4, 2023

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical data and detailed its plans to advance two new RNAi-based obesity candidates, ARO-INHBE and ARO-ENPP1.

The preclinical results, presented at the 2023 Obesity Week conference in San Diego, California, demonstrate that ARO-INHBE substantially silenced hepatic expression of the INHBE gene, leading to significant reductions in body weight and adiposity in obese animal models.

ARO-ENPP1, the second candidate, also showed promising preclinical results, reducing body weight and improving metabolic parameters in obese animal models. The data suggest that targeting ENPP1 with RNAi therapeutics may be a potential approach for the treatment of obesity.

Arrowhead plans to initiate Phase 1 clinical trials for both ARO-INHBE and ARO-ENPP1 in the second half of 2023. The company believes that these candidates have the potential to become first-in-class treatments for obesity.

"We are excited to advance these two promising RNAi-based candidates into clinical development," said Christopher Anzalone, Ph.D., Arrowhead's president and CEO. "Obesity is a major global health concern, and we believe that our RNAi platform has the potential to develop transformative therapies for this disease."

Arrowhead is a leading biopharmaceutical company focused on developing RNAi-based therapies for a wide range of diseases. The company's RNAi platform is based on the discovery of small interfering RNAs (siRNAs), which are naturally occurring molecules that regulate gene expression. Arrowhead's siRNAs are designed to target specific genes that are involved in the development and progression of disease.

For more information, please visit www.arrowheadpharma.com.